Article
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.
Nature medicine - 1 May 2018
Shen Jianfeng, Ju Zhenlin, Zhao Wei, Wang Lulu, Peng Yang, Ge Zhongqi, Nagel Zachary D, Zou Jun, Wang Chen, Kapoor Prabodh, Ma Xiangyi, Ma Ding, Liang Jiyong, Song Shumei, Liu Jinsong, Samson Leona D, Ajani Jaffer A, Li Guo-Min, Liang Han, Shen Xuetong, Mills Gordon B, Peng Guang
Abstract excerpt
ARID1A (the AT-rich interaction domain 1A, also known as BAF250a) is one of the most commonly mutated genes in cancer1,2. The majority of ARID1A mutations are inactivating mutations and lead to loss of ARID1A expression 3 , which makes ARID1A a poor therapeutic target. Therefore, it is of clinical importance to identify molecular consequences of ARID1A deficiency that create therapeutic vulnerabilities in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.